BlackRock Inc. Has $928.56 Million Position in NeoGenomics, Inc. (NASDAQ:NEO)

Don Miller 2021-02-21 10:02

[embedded content]

NeoGenomics logo BlackRock Inc. lifted its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 5.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 17,246,570 shares of the medical research company’s stock after purchasing an additional 861,490 shares during the quarter. BlackRock Inc. owned about 0.16% of NeoGenomics worth $928,557,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of NEO. Valeo Financial Advisors LLC grew its holdings in NeoGenomics by 150.0% during the 3rd quarter. Valeo Financial Advisors LLC now owns 1,000 shares of the medical research company’s stock worth $37,000 after acquiring an additional 600 shares during the period. Fiduciary Planning LLC acquired a new stake in NeoGenomics during the 3rd quarter worth $41,000. FinTrust Capital Advisors LLC grew its holdings in NeoGenomics by 27.0% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 1,270 shares of the medical research company’s stock worth $47,000 after acquiring an additional 270 shares during the period. RWM Asset Management LLC acquired a new stake in NeoGenomics during the 4th quarter worth $73,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in NeoGenomics during the 3rd quarter worth $55,000. 91.06% of the stock is owned by institutional investors and hedge funds.

Get NeoGenomics alerts:

NEO opened at $56.56 on Friday. The stock has a market capitalization of $6.28 billion, a P/E ratio of -1,884.71 and a beta of 0.79. NeoGenomics, Inc. has a 12 month low of $20.47 and a 12 month high of $61.57. The firm’s fifty day simple moving average is $54.87 and its 200 day simple moving average is $45.42. The company has a current ratio of 6.54, a quick ratio of 6.22 and a debt-to-equity ratio of 0.25.

In other NeoGenomics news, Director Steven C. Jones sold 130,000 shares of the business’s stock in a transaction dated Monday, December 7th. The shares were sold at an average price of $48.55, for a total transaction of $6,311,500.00. Following the sale, the director now directly owns 72,932 shares of the company’s stock, valued at approximately $3,540,848.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider George Cardoza sold 52,926 shares of the business’s stock in a transaction dated Tuesday, November 24th. The stock was sold at an average price of $45.19, for a total transaction of $2,391,725.94. Following the sale, the insider now directly owns 423,828 shares in the company, valued at $19,152,787.32. The disclosure for this sale can be found here. Insiders sold a total of 295,809 shares of company stock worth $14,338,460 over the last ninety days. 6.50% of the stock is currently owned by insiders.

Several equities analysts have recently issued reports on NEO shares. Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a report on Thursday, February 11th. Needham & Company LLC boosted their price target on shares of NeoGenomics from $39.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Benchmark boosted their price target on shares of NeoGenomics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. SVB Leerink boosted their price target on shares of NeoGenomics from $50.00 to $60.00 and gave the company an “outperform” rating in a report on Friday, January 8th. Finally, CIBC raised shares of NeoGenomics to an “outperformer” rating and boosted their price target for the company from $10.50 to $14.50 in a report on Monday, October 26th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $43.58.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.